Get started
Author

Sheryl Coppola

Observed name: S. Coppola
ORCID: 0000-0002-1866-5962
Observed ORCID: 0000-0002-1866-5962
OpenAlex ID: A5050858240
A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.
2021 · Anthony W. Tolcher, Benedito A. Carneiro, et al. · Journal of Clinical Oncology · 33
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study
2020 · Hari V. Kalluri, Ryota Kikuchi, et al. · Clinical and Translational Science · 29
PDF
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2021 · Cristina Gasparetto, Kristian M. Bowles, et al. · Clinical Lymphoma Myeloma & Leukemia · 20
PDF
A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.
2020 · Maria-Victoria Mateos, Philippe Moreau, et al. · Journal of Clinical Oncology · 17
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
2020 · Jonathan L. Kaufman, Rachid C. Baz, et al. · Journal of Clinical Oncology · 13
Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
2021 · Mohamed‐Eslam F. Mohamed, Sheryl Coppola, et al. · Clinical Pharmacology in Drug Development · 11
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
2023 · Mohamed Badawi, Sheryl Coppola, et al. · Hematological Oncology · 7
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial
2024 · Scott R. Solomon, Bayard L. Powell, et al. · Cancers · 5
PDF
Population Pharmacokinetic-Pharmacodynamic Modeling of Neutrophil and Platelet Count for Lower-Intensity Therapy of CPX-351 Combined with Venetoclax in Acute Myeloid Leukemia
2023 · Yali Liang, Sarah F Cook, et al. · Blood · 2
AB0478 Mild and moderate hepatic impairment have no clinically relevant impact on upadacitinib pharmacokinetics: results from a dedicated phase 1 study
2018 · M.-E.F. Mohamed, S. Coppola, et al. · Annals of the Rheumatic Diseases · 1
PDF
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection
2022 · Mohamed A Badawi, Sheryl Coppola, et al. · Blood
AB0479 Characterisation of the effect of renal impairment on upadacitinib pharmacokinetics
2018 · M.-E.F. Mohamed, S. Coppola, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 12
Citation count: 138
H-index: 7
I10-index: 6
Year
Topic
Type